Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)

ClinicalTrials.gov ID: NCT01397201

Public ClinicalTrials.gov record NCT01397201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 12:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Double-dummy, Placebo-controlled, Parallel-group Study to Assess and Compare Efficacy and Safety of an 8-week Treatment With BI 54903 at Doses of 45.5, 90.9 and 181.8 mcg b.i.d. Administered Via Respimat® Inhaler and Fluticasone Propionate HFA 220 mcg b.i.d. in Patients With Asthma Inadequately Controlled on Low Dose ICS Therapy

Study identification

NCT ID
NCT01397201
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Boehringer Ingelheim
Industry
Enrollment
30 participants

Conditions and interventions

Conditions

Interventions

  • Placebo Drug
  • BI 54903 Drug
  • Fluticasone propionate Drug

Drug

Eligibility (public fields only)

Age range
12 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 30, 2011
Primary completion
Dec 22, 2011
Completion
Dec 22, 2011
Last update posted
Jun 22, 2022

2011

United States locations

U.S. sites
41
U.S. states
22
U.S. cities
41
Facility City State ZIP Site status
1248.6.01047 Boehringer Ingelheim Investigational Site Fountain Valley California
1248.6.01023 Boehringer Ingelheim Investigational Site Fullerton California
1248.6.01041 Boehringer Ingelheim Investigational Site Huntington Beach California
1248.6.01038 Boehringer Ingelheim Investigational Site Long Beach California
1248.6.01004 Boehringer Ingelheim Investigational Site Mission Viejo California
1248.6.01028 Boehringer Ingelheim Investigational Site Palmdale California
1248.6.01044 Boehringer Ingelheim Investigational Site Stockton California
1248.6.01034 Boehringer Ingelheim Investigational Site Walnut Creek California
1248.6.01015 Boehringer Ingelheim Investigational Site Centennial Colorado
1248.6.01035 Boehringer Ingelheim Investigational Site Aventura Florida
1248.6.01022 Boehringer Ingelheim Investigational Site Miami Florida
1248.6.01042 Boehringer Ingelheim Investigational Site Sarasota Florida
1248.6.01051 Boehringer Ingelheim Investigational Site Columbus Georgia
1248.6.01052 Boehringer Ingelheim Investigational Site Savannah Georgia
1248.6.01011 Boehringer Ingelheim Investigational Site Eagle Idaho
1248.6.01055 Boehringer Ingelheim Investigational Site Oak Lawn Illinois
1248.6.01019 Boehringer Ingelheim Investigational Site Baltimore Maryland
1248.6.01039 Boehringer Ingelheim Investigational Site North Dartmouth Massachusetts
1248.6.01037 Boehringer Ingelheim Investigational Site Ypsilanti Michigan
1248.6.01056 Boehringer Ingelheim Investigational Site Rolla Missouri
1248.6.01036 Boehringer Ingelheim Investigational Site Warrensburg Missouri
1248.6.01020 Boehringer Ingelheim Investigational Site Omaha Nebraska
1248.6.01049 Boehringer Ingelheim Investigational Site Berlin New Jersey
1248.6.01054 Boehringer Ingelheim Investigational Site Trenton New Jersey
1248.6.01010 Boehringer Ingelheim Investigational Site Verona New Jersey
1248.6.01006 Boehringer Ingelheim Investigational Site Rochester New York
1248.6.01031 Boehringer Ingelheim Investigational Site High Point North Carolina
1248.6.01045 Boehringer Ingelheim Investigational Site Cincinnati Ohio
1248.6.01005 Boehringer Ingelheim Investigational Site Gresham Oregon
1248.6.01021 Boehringer Ingelheim Investigational Site Portland Oregon
1248.6.01013 Boehringer Ingelheim Investigational Site Philadelphia Pennsylvania
1248.6.01040 Boehringer Ingelheim Investigational Site Pittsburgh Pennsylvania
1248.6.01012 Boehringer Ingelheim Investigational Site Upland Pennsylvania
1248.6.01048 Boehringer Ingelheim Investigational Site Charleston South Carolina
1248.6.01050 Boehringer Ingelheim Investigational Site Austin Texas
1248.6.01002 Boehringer Ingelheim Investigational Site Live Oak Texas
1248.6.01046 Boehringer Ingelheim Investigational Site San Antonio Texas
1248.6.01001 Boehringer Ingelheim Investigational Site Waco Texas
1248.6.01025 Boehringer Ingelheim Investigational Site Murray Utah
1248.6.01053 Boehringer Ingelheim Investigational Site Alexandria Virginia
1248.6.01030 Boehringer Ingelheim Investigational Site Tacoma Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01397201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2022 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01397201 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →